Rational design of a vaccine for Alzheimer’s disease using computationally-derived conformational B cell epitopes to selectively target toxic amyloid-beta oligomers

Using Predictive Models to Reduce Heterogeneity in Alzheimer’s Disease Clinical Trials

Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating With Composite Clinical Score of Cognition and Function in Alzheimer’s Disease